NMPA (China) approves Gavreto to treat metastatic rearranged RET fusion positive NSCLC.
CStone Pharmaceuticals, announced that the National Medical Products Administration (NMPA) of China has approved Gavreto (pralsetinib) capsules for the treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) after platinum-based chemotherapy.
Discovered by CStone’s partner Blueprint Medicines, Gavreto is China’s first approved selective RET inhibitor, as well as CStone’s first approved precision therapy in China.
Professor Yi-long Wu of Guangdong Provincial People’s Hospital, a Principal Investigator on the ARROW study said, “The development of a RET-targeted therapy is a huge breakthrough in precision medicine for lung cancer. The approval of Gavreto in China, greatly supported by the strong trial results from the ARROW study, may change standards of care for patients with RET fusion-positive NSCLC.”
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.